These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 12092657)
1. K-RAS mutation in transitional cell carcinoma of urinary bladder. Ayan S; Gokce G; Kilicarslan H; Ozdemir O; Yildiz E; Gultekin EY Int Urol Nephrol; 2001; 33(2):363-7. PubMed ID: 12092657 [TBL] [Abstract][Full Text] [Related]
2. Activated H-ras gene mutations in transitional cell carcinoma of urinary bladder in a Kashmiri population. Pandith AA; Shah Z; Rasool R; Dil-Afroze ; Yousuf A; Parveen N; Wani S; Siddiqi M Tumori; 2010; 96(6):993-8. PubMed ID: 21388064 [TBL] [Abstract][Full Text] [Related]
3. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Knowles MA; Williamson M Cancer Res; 1993 Jan; 53(1):133-9. PubMed ID: 8093230 [TBL] [Abstract][Full Text] [Related]
4. Genetic aberrations of the K-ras proto-oncogene in bladder cancer in Kashmiri population. Nanda MS; Sameer AS; Syeed N; Shah ZA; Murtaza I; Siddiqi MA; Ali A Urol J; 2010; 7(3):168-73. PubMed ID: 20845292 [TBL] [Abstract][Full Text] [Related]
5. Mutations of RAS gene family in specimens of bladder cancer. Karimianpour N; Mousavi-Shafaei P; Ziaee AA; Akbari MT; Pourmand G; Abedi A; Ahmadi A; Afshin Alavi H Urol J; 2008; 5(4):237-42. PubMed ID: 19101897 [TBL] [Abstract][Full Text] [Related]
6. Activation of RAS family genes in urothelial carcinoma. Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097 [TBL] [Abstract][Full Text] [Related]
7. Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. Burchill SA; Neal DE; Lunec J Br J Urol; 1994 May; 73(5):516-21. PubMed ID: 8012773 [TBL] [Abstract][Full Text] [Related]
8. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Yamamoto S; Masui T; Murai T; Mori S; Oohara T; Makino S; Fukushima S; Tatematsu M Carcinogenesis; 1995 Oct; 16(10):2363-8. PubMed ID: 7586136 [TBL] [Abstract][Full Text] [Related]
9. [Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. Yu D; Liu F; Liang Z Zhonghua Bing Li Xue Za Zhi; 1996 Aug; 25(4):202-5. PubMed ID: 9275651 [TBL] [Abstract][Full Text] [Related]
10. Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing. Grimmond SM; Raghavan D; Russell PJ Urol Res; 1992; 20(2):121-6. PubMed ID: 1553789 [TBL] [Abstract][Full Text] [Related]
11. Ras oncogene point mutations in bladder cancer resistant to cisplatin. Wood DP; Anderson AE; Fair R; Chaganti RS Urol Res; 1992; 20(4):313-6. PubMed ID: 1509639 [TBL] [Abstract][Full Text] [Related]
12. [Low incidence of mutations in codon 12 of the c-K-ras gene in bladder cancer]. Ejarque MJ; Villanueva A; Chechile G; Regalado R; Errando C; Algaba F; Capella G; Lluis F; Villavicencio H; Vicente J Actas Urol Esp; 1995 Sep; 19(8):599-603. PubMed ID: 8669326 [TBL] [Abstract][Full Text] [Related]
13. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772 [TBL] [Abstract][Full Text] [Related]
14. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Saito S; Hata M; Fukuyama R; Sakai K; Kudoh J; Tazaki H; Shimizu N Int J Urol; 1997 Mar; 4(2):178-85. PubMed ID: 9179693 [TBL] [Abstract][Full Text] [Related]
15. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. Fitzgerald JM; Ramchurren N; Rieger K; Levesque P; Silverman M; Libertino JA; Summerhayes IC J Natl Cancer Inst; 1995 Jan; 87(2):129-33. PubMed ID: 7707384 [TBL] [Abstract][Full Text] [Related]
16. Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Olderøy G; Daehlin L; Ogreid D Anticancer Res; 1998; 18(4A):2675-8. PubMed ID: 9703927 [TBL] [Abstract][Full Text] [Related]
17. [Gene amplification in bladder tumors]. Pinto MC; de Carvalho AP Actas Urol Esp; 1997; 21(10):942-9. PubMed ID: 9494156 [TBL] [Abstract][Full Text] [Related]
18. Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis. Ota T; Asamoto M; Toriyama-Baba H; Yamamoto F; Matsuoka Y; Ochiya T; Sekiya T; Terada M; Akaza H; Tsuda H Carcinogenesis; 2000 Jul; 21(7):1391-6. PubMed ID: 10874018 [TBL] [Abstract][Full Text] [Related]
19. p53 mutations in transitional cell carcinomas of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine. Masui T; Dong Y; Yamamoto S; Takada N; Nakanishi H; Inada K; Fukushima S; Tatematsu M Cancer Lett; 1996 Jul; 105(1):105-12. PubMed ID: 8689624 [TBL] [Abstract][Full Text] [Related]
20. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]